Search
Displaying 171–180 of 664 for “retinitis clinical trial”
-
VISIONS 2024, the global conference of the Foundation Fighting Blindness, provides an excellent opportunity to connect with others from the blind and low vision community and learn about the latest research advancements, products and services for members of our community.
-
VISIONS 2024, the global conference (June 20–21, 2024) of the Foundation Fighting Blindness, provides an excellent opportunity to connect with others from the blind and low vision community and learn about the latest research advancements, products and services for members of our community.
-
Research News
Small data sets present challenges for developing rare disease AI tools
-
Choroideremia Gene Therapy Improves Vision in Human Study
Research NewsResearchers were able to improve vision in five of six people with choroideremia participating in a clinical trial.
-
FFB-CRI Launching Natural History Study for People with USH2A Mutations
Research NewsThe study — known as RUSH2A (“R” stands for “rate of progression”) — is beginning in spring 2017 and will take place at about 20 clinical sites around the world. RUSH2A investigators will use a variety of technologies to monitor changes in vision and retinal structure to document and analyze disease progression.
-
Research News
Research has suggested that DHA in your diet is good for preventing and treating cardiovascular diseases, neurological conditions, depression and a slew of other conditions and maladies, including those that affect the retina.
-
AGTC Reports Promising Interim Results for XLRP and Achromatopsia Gene Therapy Trials
Research NewsAGTC used Foundation’s My Retina Tracker registry to recruit patients for trials
-
FFB Provides Four Career Development Awards to Up-and-Coming Clinical Researchers
Research NewsEach recipient will receive a total of $375,000 over five years to help build an independent research program in addition to their clinical practices.
-
Eye on the Cure Podcast | Episode 48: Jami Kern, PhD
Eye on the CureJune 16, 2023. Jami Kern, PhD, chief clinical officer at Nacuity Pharmaceuticals, talks with host Ben Shaberman about NACA, the company’s emerging gene-agnostic therapy for Usher syndrome and retinitis pigmentosa in a Phase 2 clinical trial in Australia. Their conversation includes a discussion about oxidative stress, which NACA is designed to mitigate, and timing for the efficacy readout from the Phase 2 study.
-
Eye on the Cure Podcast | Episode 45: Henry Klassen, MD, PhD
Eye on the CureApril 28, 2023. Henry Klassen, MD, PhD, co-founder of jCyte and clinical researcher at UC Irvine, talks to host Ben Shaberman about jCyte’s clinical trial results and future plans for developing its cell-based therapy for preserving vision caused by retinitis pigmentosa, Usher syndrome, and related retinal conditions.
%20(7).png)
